Navigating HER2+ Brain Metastases: Emerging Insights

EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals

EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer

EP: 3.HER2+ Breast Cancer: Anthracycline Considerations

EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends

EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring

EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer

EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer

EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials

EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer

EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases

Now Viewing

EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights

EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges

EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer

EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care

This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.

O’Shaughnessy and McArthur discuss recent advancements in the treatment of brain metastases in HER2-positive breast cancer. McArthur highlights subgroup analyses from the HER2CLIMB trial, revealing a significant survival advantage of the tucatinib-containing regimen, particularly in patients with brain metastases. She emphasizes the paradigm-shifting impact of this data on treatment approaches. Additionally, the TUXEDO phase 2 trial explores the efficacy of trastuzumab deruxtecan (T-DXd) in patients with active brain metastases, showing impressive progression-free survival of nearly 2 years in a high-risk population. The I-ROSETTE study from a Japanese group evaluates T-DXd in patients with leptomeningeal disease, demonstrating promising overall survival rates. The discussion underscores the evolving landscape of HER2-positive breast cancer treatment, with emerging strategies addressing the unmet needs of patients with brain and leptomeningeal involvement.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.